BioCentury | May 16, 2020
Product Development

Daily Chart: ide-cel’s challengers in the BCMA pipeline

Wednesday’s refusal-to-file letter for idecabtagene vicleucel slows the cell therapy from bluebird bio Inc. and Bristol Myers Squibb Co. in the race to market a product targeting BCMA to treat multiple myeloma (see “Refusal-to-File Letter...
BC Week In Review | Mar 8, 2019
Company News

CARsgen's BCMA CAR T moving to clinic in China

CARsgen said CT053 (CAR-BCMA) received IND clearance from China's National Medical Products Administration (NMPA). CARsgen Therapeutics Co. Ltd. (Shanghai, China) said it is also planning to submit this year an IND to FDA for the...
Items per page:
1 - 2 of 2